NCT06937411View on ClinicalTrials.gov

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

88

Participants

Timeline

Start Date

February 13, 2023

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions

Healthy

Interventions

DRUG

LY4100511

Administered orally

Trial Locations (1)

M23 (QZ

The Medicines Evaluation Unit Ltd., Manchester

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY